KIR3DL2 IS A BIOMARKER AND A THERAPEUTIC TARGET USEFUL FOR RESPECTIVELY PREVENTING AND TREATING A SUBSET OF CUTANEOUS AND NON-CUTANEOUS PERIPHERAL T-CELL LYMPHOMAS
摘要
The present invention relates to a ligand molecule that specifically binds to KTR3DL2 at the surface of KTR3DL2 expressing malignant T-cells for the treatment of lymphomas. It also relates to the in vitro use of a level of expression of KIR3DL2 is a biomarker useful for diagnosing and/or monitoring a lymphoma.
申请公布号
WO2014191936(A1)
申请公布日期
2014.12.04
申请号
WO2014IB61786
申请日期
2014.05.28
申请人
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE;ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS;UNIVERSITE PARIS-EST CRETEIL VAL DE MARNE
